California Insurance Commissioner Sues AbbVie over Humira

Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches
AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023

Ferumoxytol Injection Receives New Indication, & Application for GP2017 Moves Ahead

Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab

Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
Express Scripts Tries to Rein in Pricey Inflammatory Drugs
